MicroRNA137-loaded lipid nanoparticles regulate synaptic proteins in the prefrontal cortex

Area of Science:

• Neuroscience
• Genetics
• Nanotechnology

Background:

• Schizophrenia (SCZ) risk is linked to genetic variants in MIR137, the gene for microRNA137 (miR137).
• Dysregulated miR137 and its targets are implicated in SCZ-related synaptic dysfunction.
• Lipid nanoparticles (LNPs) are promising for RNA delivery, but brain-specific applications are limited.

Purpose of the Study:

• To investigate the potential of engineered LNPs for brain-specific delivery of miR137.
• To assess the therapeutic capacity of miR137 delivered via LNPs for SCZ-related molecular targets.

Main Methods:

• LNPs were engineered to encapsulate and deliver miR137 and mRNA payloads.
• In vitro studies used neuroblastoma cells to confirm LNP cargo release and target inhibition.
• In vivo studies in mice assessed LNP biodistribution, cell-specific expression (neuronal vs. glial), and proteomic changes in the prefrontal cortex (PFC).

Main Results:

• LNPs successfully released miR137 cargo and inhibited target transcripts in neuroblastoma cells.
• In vivo, LNP-delivered mRNA localized to the mouse PFC, with preferential expression in neurons.
• Quantitative proteomics revealed that miR137 modulated glutamatergic synaptic protein networks relevant to SCZ.

Conclusions:

• Engineered LNPs can deliver RNA therapeutics, including miR137, to specific brain regions.
• This LNP technology demonstrates potential for targeting molecular pathways implicated in SCZ.
• Further development of brain-specific LNPs could lead to novel treatments for central nervous system disorders.